Table 4. Quasispecies analysis of HCVp0 populations passaged in the absence or presence of ribavirin and guanosine^a.

Ribavirin conc. (µM)a	Guanosine conc. (µM)a	Number of nt analyzed (clones/haplotypes)b	Mutation frequencyc	Nucleotide diversityc π. 103 (95% CI)
0	0	29,704 (22/18)	7.7×10−4	1.16 (0.93–1.51)
0	200	30,493 (24/17)	8.5×10−4	1.36 (1.09–1.68)
50	0	23,766 (17/17)	1.4×10−3	1.54 (1.16–2.11)
50	200	35,979 (27/17)	9.2×10−4	1.39 (1.17–1.72)
100	0	21,396 (20/20)	2.0×10−3	2.43 (1.99–3.44)
100	200	38,125 (28/26)	1.7×10−3	2.36 (2.04–2.79)

^aThe populations analyzed correspond to the infections at an initial MOI of 0.1 to 0.2 TCID₅₀/cell described in Fig. 5a. About 25% to 50% of clones analyzed did not contain the full length sequence expected from the primers used; when the alignment of the sequenced region was correct such clones were entered in the calculation. The HCV genome residue numbering corresponds to the JFH-1 genome (accession number #AB047639). The NS5A-coding region (nucleotides 6269 to 7666) was analyzed.

^bThe parenthesis indicates the number of clones analyzed, followed by the number of haplotypes (number of different RNA sequences); some clones did not contain the full length sequence; when the alignment of the sequenced region was correct such clones were entered in the calculation.

^cMutation frequency and nucleotide diversity are defined in Table 1 legend and Materials and Methods. Mutation types are summarized in Fig. 4d and their position in the HCV genome and deduced amino acid substitutions are given in Table S6.